Nyra is developing a transcatheter technology (CARLEN), which modifies the native mitral valve leaflets with a proprietary implant, to correct for deficiencies that otherwise lead to mitral regurgitation, while preserving the physiological valve geometry.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/23/22 | $20,000,000 | Series A |
Broadview Ventures Epidarex Capital Georgia Research Alliance Vensana Capital  | undisclosed |
